Labcorp Holdings Inc. (LH)
NYSE:LH
Want to see LH full AI Analyst Report?
LH Stock Chart & Stats
$270.68
-$1.45(-0.62%)
At close: 4:00 PM EST
$270.68
-$1.45(-0.62%)
Day’s Range― - ―
52-Week Range$241.81 - $293.72
Previous CloseN/A
Volume103.18K
Average Volume (3M)678.09K
Market Cap
$21.23B
Enterprise Value$27.58B
Total Cash (Recent Filing)$981.10M
Total Debt (Recent Filing)$7.24B
Price to Earnings (P/E)22.8
Beta0.33
Next Earnings
Jul 30, 2026EPS Estimate
4.79Next Dividend Ex-DateN/A
Dividend Yield1.14%
Share Statistics
EPS (TTM)11.37
Shares Outstanding82,000,000
10 Day Avg. Volume562,157
30 Day Avg. Volume678,091
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)2.42
Price to Sales (P/S)1.50
P/FCF Ratio17.31
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit7.02
Enterprise Value/Ebitda13.29
Forecast
1Y Price Target
$309.86Price Target Upside14.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)18.02
Revenue Forecast (FY)$14.69B
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationSustained and improving free cash flow provides durable financial optionality: it funds capital expenditures (~4% of revenue guidance), dividends, M&A and buybacks while supporting deleveraging. Over 2–6 months this underpins balance-sheet flexibility and strategic investments.
Robust BLS Backlog And Book-to-billA large, visible Biopharma Lab Services backlog and >1.0 book-to-bill give multi-quarter revenue visibility and support margin leverage as contracted trials convert. This durable pipeline cushions organic volatility and sustains outsourcing-driven revenue for the coming 12 months.
Diagnostics Scale And Margin ExpansionRecurring clinical testing with scale across a large lab network, steady organic volumes and ongoing price/mix gains support structural margins. Operational improvements and mix shifts toward higher-margin specialty assays help sustain operating profitability over the medium term.
Bears Say
Regulatory And Reimbursement RiskUncertain reimbursement policy outcomes (PAMA/RESULTS Act, CRUSH) threaten pricing and test access across diagnostics. These structural regulatory risks can compress margins or reduce volumes for specific assays for many quarters, making revenue and margin forecasts less certain.
Elevated Leverage And Covenanted Term LoanMaterial debt and a recently funded $750M term loan increase near-term leverage and impose covenant limits that can restrict capital allocation. This constrains M&A, buybacks or aggressive reinvestment if free cash flow underperforms, affecting strategic flexibility over multiple quarters.
Profitability And Cash Conversion Below Historic PeaksMargins and cash conversion remain meaningfully below 2021–2022 peaks, indicating structural pressures (pricing, mix, reimbursement). Lower cash conversion relative to net income raises earnings quality questions and limits rapid balance-sheet repair if headwinds persist.
Labcorp Holdings News
LH FAQ
What was Labcorp Holdings Inc.’s price range in the past 12 months?
Labcorp Holdings Inc. lowest stock price was $241.81 and its highest was $293.72 in the past 12 months.
What is Labcorp Holdings Inc.’s market cap?
Labcorp Holdings Inc.’s market cap is $21.23B.
When is Labcorp Holdings Inc.’s upcoming earnings report date?
Labcorp Holdings Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 54 days.
How were Labcorp Holdings Inc.’s earnings last quarter?
Labcorp Holdings Inc. released its earnings results on Apr 30, 2026. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.11 by $0.14.
Is Labcorp Holdings Inc. overvalued?
According to Wall Street analysts Labcorp Holdings Inc.’s price is currently Undervalued.
Does Labcorp Holdings Inc. pay dividends?
Labcorp Holdings Inc. pays a Quarterly dividend of $0.72 which represents an annual dividend yield of 1.14%. See more information on Labcorp Holdings Inc. dividends here
What is Labcorp Holdings Inc.’s EPS estimate?
Labcorp Holdings Inc.’s EPS estimate is 4.79.
How many shares outstanding does Labcorp Holdings Inc. have?
Labcorp Holdings Inc. has 82,000,000 shares outstanding.
What happened to Labcorp Holdings Inc.’s price movement after its last earnings report?
Labcorp Holdings Inc. reported an EPS of $4.25 in its last earnings report, beating expectations of $4.11. Following the earnings report the stock price went down -0.132%.
Which hedge fund is a major shareholder of Labcorp Holdings Inc.?
Currently, no hedge funds are holding shares in LH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Labcorp Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$309.86 (14.47% Upside)
$309.86 (14.47% Upside)
Blogger Sentiment
Bullish
LH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 60.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.67%
12-Months-Change
Fundamentals
Return on Equity
10.91%
Trailing 12-Months
Asset Growth
8.43%
Trailing 12-Months
Company Description
Labcorp Holdings Inc.
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
LH Company Deck
LH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominately positive picture: solid top-line growth, double-digit EPS improvement, margin expansion, healthy BLS backlog and raised/narrowed guidance. Management highlighted strong progress on strategic partnerships, product launches and AI/technology initiatives. Key challenges include weather-driven volume disruption, Early Development transitional actions, regulatory/reimbursement uncertainty (CRUSH, PAMA/RESULTS Act), and modest short-term cash flow/leverage considerations. Overall, positives around organic growth, profitability and a robust deal/product pipeline outweigh the identified headwinds.View all LH earnings summariesLH Revenue Breakdown
77.96% Dx
22.21% BLS
-0.16% Intercompany eliminations
LH Stock 12 Month Forecast
Average Price Target
$309.86
▲(14.47% Upside)
Technical Analysis
Ownership Overview
0.33% Insiders
29.63% Mutual Funds
20.97% Other Institutional Investors
23.25% Public Companies and Individual Investors